Press release content from PR Newswire. The AP news staff was not involved in its creation.
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
February 1, 2021 GMT
Clover LOGO (PRNewsfoto/三叶草生物制药有限公司)
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
CHENGDU, China, Feb. 1, 2021 /PRNewswire/ Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines and therapeutics for the world’s most debilitating diseases, today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its